Drug Search Results
More Filters [+]

Lucerastat

Alternative Names: lucerastat
Latest Update: 2024-08-08
Latest Update Note: Clinical Trial Update

Product Description

Idorsia is developing Lucerastat as a treatment for Fabry disease. (Sourced from: https://www.idorsia.com/media/news-details?newsId=2608540)

Mechanisms of Action: GCS Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Idorsia
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lucerastat

Countries in Clinic: Australia, Austria, Belgium, Canada, France, Germany, Norway, Poland, Spain, United Kingdom, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Fabry Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ID-069A302

P3

Active, not recruiting

Fabry Disease

2025-10-29

2018-002210-12

P3

Unknown status

Fabry Disease

2025-09-18

Recent News Events